AstraZeneca Considering $400 Billion Merger with Bristol Myers Squibb
British pharmaceutical giant AstraZeneca is reportedly in talks to merge with US-based Bristol Myers Squibb, creating a combined entity valued at around £300 billion ($400 billion). The deal would be one of the largest mergers ever and could raise concerns about AstraZeneca's continued ties to the UK. Both companies are major players: AstraZeneca is currently worth approximately £196 billion, while Bristol Myers Squibb has a market value of around $133 billion. The proposed merger comes as AstraZeneca continues its strategic shift toward the US. In recent years, it upgraded its New York listing and signed agreements with the Trump administration to invest in American manufacturing. Despite these moves, AstraZeneca insists on maintaining its headquarters in Cambridge and retaining a London Stock Exchange listing. The deal echoes past attempts by Pfizer to acquire AstraZeneca over a decade ago, which were ultimately rejected due to political and board resistance.
Topics: AstraZeneca Bristol Myers Squibb mergers and acquisitions pharmaceuticals